PCSA processapharmaceuticals.com: Long-Term Debt to Capital Coefficient
Processa Pharmaceuticals (PCSA) relies on third-party centers and plants for drug development. The long-term debt-to-equity trend illustrates financial stability, where 0.00 shows the current value of the metric. The company is modernizing chemotherapy to reduce toxicity, yet it faces a funding shortage and significant risks of clinical trial failure amid fierce competition.
%20Long-Term%20Debt%20to%20Capital&width=1200&height=400&colorIndex=0&v=mvq8bmkb.8d-7aozthc&start=20220704&end=20261027&filename=GURU_Markets_-_PCSA_-_Processa-Pharmaceuticals_-_Long-Term-Debt-to-Capital "Processa Pharmaceuticals Inc. - PCSA Long-Term Liabilities to Capital (period 07/04/2022 - 10/27/2026) | 👁️GURU.Markets👁️")
Analytical breakdowns and data insights for company Processa Pharmaceuticals Inc. (PCSA)
This ratio measures the proportion of long-term liabilities relative to equity, determining the company's degree of financial leverage. An increase in this metric signals a rising credit burden, whereas a decrease may reflect either debt repayment or growth in capitalization. By analyzing the long-term debt-to-equity ratio on GURU.Markets, an investor gains insight into the actual stability of the balance sheet structure. For Processa Pharmaceuticals (PCSA), a low level of borrowing is critically important. This enables the company to effectively utilize the Regulatory Science platform to modernize chemotherapy, leveraging strong pricing power and inelastic demand.